Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.

The journal of allergy and clinical immunology. In practice - 1 Jan 2000

Casale Thomas B, Bateman Eric D, Vandewalker Mark, Virchow J Christian, Schmidt Hendrik, Engel Michael, Moroni-Zentgraf Petra, Kerstjens Huib A M

Abstract excerpt

BACKGROUND: Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting β2-agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma. OBJECTIVE: To assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status. METHODS: In this exploratory study, data from 4 phase III trials were analyzed: once-daily...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Inhalation
Share to Adrenal Cortex Hormones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Adrenergic beta-2 Receptor Agonists

Share to Asthma

Share to Bronchodilator Agents

Share to Drug Combinations

Share to Drug Synergism

Share to Th2 Cells

Source

Identifiers

PMID: 29174062
DOI: 10.1016/j.jaip.2017.08.037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.PMID 29174062Read ↗

Tiotropium Is Efficacious in 6- to 17-Year-Olds with Asthma, Independent of T2 PhenotypeSemantic proximity Read ↗

New and existing pharmacotherapeutic options for persistent asthma and COPD.Semantic proximity Read ↗

Biomarker-guided withdrawal of inhaled corticosteroids in asthma patients with a non-T2 inflammatory phenotype - a randomized controlled trial study protocol.Semantic proximity Read ↗

¿p#1 Multidomain Clinical and Biological Remission with Tezepelumab in Severe Asthma: A 12-Month Multicentre Real-World StudySemantic proximity Read ↗

The 5T approach in asthma: Triple Therapy Targeting Treatable Traits.Semantic proximity Read ↗

Biologics in severe asthma: the overlap endotype - opportunities and challenges.Semantic proximity Read ↗

Biologic Therapy and Novel Molecular Targets of Severe Asthma.Semantic proximity Read ↗

Difficult-to-Control Asthma Management in Adults.Semantic proximity Read ↗

Phenotypic predictors of response to oral glucocorticosteroids in severe asthma.Semantic proximity Read ↗

Severe asthma and personalized approach in the choice of biologic.Semantic proximity Read ↗

Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.Semantic proximity Read ↗

A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.